In the article: Zai G, Brandl EJ, Müller DJ, Richter MA, Kennedy JL. Pharmacogenetics of antidepressant treatment in obsessive–compulsive disorder: an update and implications for clinicians. Pharmacogenomics 15(8), 1147–1157 (2014) (www.tandfonline.com/doi/pdf/10.2217/pgs.14.83), the BTBD3 gene was incorrectly referred to in the following paragraph:
Our pharmacogenetic study in the remote regulatory regions tested markers with potential functional impact on several interesting OCD candidate genes: BDNF, FAIM2, FUT2 and BDBT3 (Supplementary Table 1; previously described in the ‘serotonergic system genes‘ section) [46]. Significant results were observed between one SNP regulating the FAIM2 gene and any SRI(s) or any SSRI(s) response (p = 0.017–0.045). BDBT3 was one of the top hit genes from the recent GWAS of OCD [17]. BDBT3 has multiple cellular functions including the regulation of dendritic orientation [62], cytosketeton dynamics, transcriptional regulation, ion channel assembly and gating, protein ubiquitination and degradation [63]. One of its close family of transcription factors, BTBD9, has been found to be associated with Tourette syndrome, which is frequently comorbid with OCD [64]; however, further study of its role in OCD is needed.
The correct paragraph is shown below:
Our pharmacogenetic study in the remote regulatory regions tested markers with potential functional impact on several interesting OCD candidate genes: BDNF, FAIM2, FUT2 and BTBD3 (Supplementary Table 1; previously described in the ‘serotonergic system genes‘ section) [46]. Significant results were observed between one SNP regulating the FAIM2 gene and any SRI(s) or any SSRI(s) response (p = 0.017–0.045). BTBD3 was one of the top hit genes from the recent GWAS of OCD [18]. BTBD3 has multiple cellular functions including the regulation of dendritic orientation [62], cytosketeton dynamics, transcriptional regulation, ion channel assembly and gating, protein ubiquitination and degradation [63]. One of its close family of transcription factors, BTBD9, has been found to be associated with Tourette syndrome, which is frequently comorbid with OCD [64]; however, further study of its role in OCD is needed.
The authors and editors of Pharmacogenomics would like to sincerely apologize for any inconvenience caused.